1. Home
  2. IMAB vs TBI Comparison

IMAB vs TBI Comparison

Compare IMAB & TBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMAB
  • TBI
  • Stock Information
  • Founded
  • IMAB 2014
  • TBI 1985
  • Country
  • IMAB United States
  • TBI United States
  • Employees
  • IMAB N/A
  • TBI N/A
  • Industry
  • IMAB Biotechnology: Pharmaceutical Preparations
  • TBI Professional Services
  • Sector
  • IMAB Health Care
  • TBI Consumer Discretionary
  • Exchange
  • IMAB Nasdaq
  • TBI Nasdaq
  • Market Cap
  • IMAB 200.9M
  • TBI 204.9M
  • IPO Year
  • IMAB 2020
  • TBI 1996
  • Fundamental
  • Price
  • IMAB $2.11
  • TBI $7.35
  • Analyst Decision
  • IMAB Strong Buy
  • TBI Buy
  • Analyst Count
  • IMAB 3
  • TBI 1
  • Target Price
  • IMAB $6.33
  • TBI $10.00
  • AVG Volume (30 Days)
  • IMAB 392.1K
  • TBI 177.0K
  • Earning Date
  • IMAB 05-15-2025
  • TBI 08-04-2025
  • Dividend Yield
  • IMAB N/A
  • TBI N/A
  • EPS Growth
  • IMAB N/A
  • TBI N/A
  • EPS
  • IMAB N/A
  • TBI N/A
  • Revenue
  • IMAB N/A
  • TBI $1,534,794,000.00
  • Revenue This Year
  • IMAB N/A
  • TBI $0.80
  • Revenue Next Year
  • IMAB N/A
  • TBI $6.90
  • P/E Ratio
  • IMAB N/A
  • TBI N/A
  • Revenue Growth
  • IMAB N/A
  • TBI N/A
  • 52 Week Low
  • IMAB $0.60
  • TBI $3.45
  • 52 Week High
  • IMAB $3.08
  • TBI $12.29
  • Technical
  • Relative Strength Index (RSI)
  • IMAB 49.47
  • TBI 62.14
  • Support Level
  • IMAB $2.01
  • TBI $6.87
  • Resistance Level
  • IMAB $2.25
  • TBI $7.78
  • Average True Range (ATR)
  • IMAB 0.13
  • TBI 0.34
  • MACD
  • IMAB -0.03
  • TBI 0.07
  • Stochastic Oscillator
  • IMAB 25.00
  • TBI 75.57

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

About TBI TrueBlue Inc.

TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.

Share on Social Networks: